ES8400877A1 - Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b). - Google Patents

Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).

Info

Publication number
ES8400877A1
ES8400877A1 ES514712A ES514712A ES8400877A1 ES 8400877 A1 ES8400877 A1 ES 8400877A1 ES 514712 A ES514712 A ES 514712A ES 514712 A ES514712 A ES 514712A ES 8400877 A1 ES8400877 A1 ES 8400877A1
Authority
ES
Spain
Prior art keywords
yeast
hbsag
synthesis
purified
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES514712A
Other languages
English (en)
Other versions
ES514712A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23113710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8400877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of ES8400877A1 publication Critical patent/ES8400877A1/es
Publication of ES514712A0 publication Critical patent/ES514712A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SINTESIS DE HBSAG (ANTIGENO SUPERFICIAL DE LA HEPATITIS B) EN LEVADURAS.SE CULTIVAN CELULAS DE LEVADURA QUE HAN SIDO TRANSFORMADAS POR UN VECTOR DE TRANSFERENCIA DE DNA QUE COMPRENDE UN SEGMENTO QUE CODIFICA PARA EL ANTIGENO SUPERFICIAL DE LA HEPATITIS B. SE PREPARA UN EXTRACTO DE LAS CELULAS DE LEVADURA. SE PURIFICA EL ANTIGENO SUPERFICIAL DE LA HEPATITIS B DEL EXTRACTO. OPCIONALMENTE SE PREPARA UNA VACUNA POR ADICION DEL ANTIGENO SUPERFICIAL DE LA HEPATITIS B SINTETIZADO POR LA LEVADURA A UN MEDIO FISIOLOGICAMENTE ACEPTABLE. TAMBIEN PUEDEN PREPARARSE ANTICUERPOSCONTRA EL ANTIGENO SUPERFICIAL DE LA HEPATITIS B SINTETIZADO POR LA LEVADURA, POR INMUNIZACION DE UN ANIMAL CON EL ANTIGENO SUPERFICIAL DE LA HEPATITIS B SINTETIZADO POR LA LEVADURA Y PURIFICACION DEL ANTICUERPO PROCEDENTE DEL SUERO DEL ANIMAL.
ES514712A 1981-08-04 1982-08-03 Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b). Granted ES514712A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28991581A 1981-08-04 1981-08-04

Publications (2)

Publication Number Publication Date
ES8400877A1 true ES8400877A1 (es) 1983-11-16
ES514712A0 ES514712A0 (es) 1983-11-16

Family

ID=23113710

Family Applications (1)

Application Number Title Priority Date Filing Date
ES514712A Granted ES514712A0 (es) 1981-08-04 1982-08-03 Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).

Country Status (12)

Country Link
EP (1) EP0072318B1 (es)
JP (1) JPS5877823A (es)
AT (1) ATE123225T1 (es)
CA (1) CA1341642C (es)
DE (2) DE3280186D1 (es)
DK (2) DK163931C (es)
ES (1) ES514712A0 (es)
GR (1) GR76274B (es)
HK (1) HK64591A (es)
IE (1) IE65996B1 (es)
PT (1) PT75374B (es)
SG (1) SG58191G (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
EP0105149B1 (en) * 1982-08-16 1990-05-16 Science and Technology Agency, Minister's Secretariat, Director of Finance Division Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
JPS60104020A (ja) * 1983-10-14 1985-06-08 メルク　エンド　カムパニー　インコーポレーテツド Ａ型肝炎‐タンパク質サブユニツト抗原
DE3587759T2 (de) * 1984-05-11 1994-07-07 Chiron Corp Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
DE3585578D1 (de) * 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3689899T2 (de) * 1985-04-08 1994-09-15 Amgen Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
JPH07106141B2 (ja) * 1985-08-15 1995-11-15 アムジエン 酵母細胞から外来遺伝子生成物の発現を増進させるための培地および方法
JP2810364B2 (ja) * 1985-10-04 1998-10-15 ジ・アップジョン・カンパニー 偽狂犬病ウイルス蛋白質
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
WO1988003562A1 (en) * 1986-11-01 1988-05-19 Oxford Gene Systems Limited Particulate hybrid hiv antigens
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
IL86833A0 (en) 1987-06-22 1988-11-30 Medico Labs Peptide containing immunogenic particles
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
NZ228948A (en) * 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JPH0314840A (ja) * 1988-12-28 1991-01-23 Kureha Chem Ind Co Ltd 弗化ビニリデン系ポリマー二軸冷延伸フィルムおよびその製造方法

Also Published As

Publication number Publication date
EP0072318B1 (en) 1990-05-30
JPH0526798B2 (es) 1993-04-19
DK114791A (da) 1991-06-14
DK114791D0 (da) 1991-06-14
EP0072318A3 (en) 1983-03-16
DK169152B1 (da) 1994-08-29
HK64591A (en) 1991-08-23
GR76274B (es) 1984-08-04
DK163931C (da) 1992-09-14
PT75374B (en) 1985-12-13
DK163931B (da) 1992-04-21
EP0072318A2 (en) 1983-02-16
SG58191G (en) 1993-02-19
PT75374A (en) 1982-09-01
ES514712A0 (es) 1983-11-16
IE65996B1 (en) 1995-11-29
CA1341642C (en) 2023-02-21
JPS5877823A (ja) 1983-05-11
DE3280468D1 (de) 1995-07-06
DK347682A (da) 1983-02-05
DE3280186D1 (de) 1990-07-05
DE3280468T2 (de) 1995-12-07
ATE123225T1 (de) 1995-06-15

Similar Documents

Publication Publication Date Title
ES8400877A1 (es) Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).
EP0291586A3 (en) Recombinant hepatitis b surface antigen and vaccine containing it
US5024938A (en) Recombinant DNA inserted with hepatitis B virus gene, mammalian cells transformed with cloned viral DNA, and production of hepatitis B virus proteins
IL95153A0 (en) Novel antigens and their production
KR880009130A (ko) 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원
KR920007683B1 (ko) HBs항원의 정제방법
ES8802162A1 (es) Un procedimiento para la preparacion de una levadura trans- formada con un plasmido recombinante insertado con el gen del virus de la hepatitis b.
AU3473489A (en) Expression of hepatisis b s and pres2proteins in methylotrophic yeasts
ES8600938A1 (es) Un procedimiento para preparar el antigeno de superficie de la hepatitis b
Wang et al. Enhanced production of hepatitis B surface antigen in NIH 3T3 mouse fibroblasts by using extrachromosomally replicating bovine papillomavirus vector
EP0248410A3 (en) Improved yeast promoter and proces for preparing heterologous protein
EP0105141A2 (en) Recombinant DNA molecules, process for their production, their use for production of hepatitis B surface antigen (HBsAg) and pharmaceutical compositions containing this HBsAg
EP0340806A3 (en) Synthesis of human virus antigens by yeast
Stephenne Production in yeast and mammalian cells of the first recombinant DNA human vaccine against hepatitis B: A technical and immunological comparison.
JPH0762033B2 (ja) Ｂ型肝炎ワクチン
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith
DE3750330D1 (de) Verfahren zur Herstellung eines Impfstoffs gegen Hepatitis B.
MY106731A (en) Novel antigens and methods therefor
SU1623207A3 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PCCA7, КОДИРУЮЩАЯ ПОВЕРХНОСТНЫЙ АНТИГЕН ВИРУСА ГЕПАТИТА В (HBsAg) И ШТАММ ДРОЖЖЕЙ ACCHAROMY CES CEREVISIAE - ПРОДУЦЕНТ ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА B